ENTO Form 3: Director Jason D. Sawyer Discloses No Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Jason D. Sawyer filed an Initial Form 3 under Section 16 reporting his relationship to Entero Therapeutics, Inc. (ENTO) as a Director. The event date is 08/11/2025 and the form is signed on 08/18/2025. The filing discloses no securities beneficially owned by the reporting person, and no derivative holdings are listed.
Positive
- Initial Form 3 filed confirming compliance with Section 16 reporting requirements on 08/18/2025
- Reporting relationship disclosed as Director, providing clarity on insider status
Negative
- No securities beneficially owned reported, indicating no disclosed equity stake by the director
- No derivative holdings disclosed, so there are no immediate option-based incentives reported
FAQ
What did Jason D. Sawyer report on the Form 3 for Entero Therapeutics (ENTO)?
He reported his status as a Director and signed the initial Form 3 on 08/18/2025, with the event date 08/11/2025.
Are there any derivative securities disclosed for Jason D. Sawyer on this Form 3?
No. Table II shows no derivative securities exercisable or outstanding for the reporting person.
What is the significance of filing a Form 3 for investors in ENTO?
A Form 3 establishes the reporting person's insider status (here, Director) and discloses any holdings; in this case it records no holdings as of the event date.